gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 30 May 2015.

Apolipoprotein A-Ia

apolipoprotein A-I, apoA-I
Top mentioned proteins: HDL, Apo, CAN, HAD, fibrillin-1
Papers on apolipoprotein A-I
Thermal Transitions in Serum Amyloid A in Solution and on the Lipid: Implications for Structure and Stability of Acute-Phase HDL.
Gursky et al., Boston, United States. In J Lipid Res, 28 Jun 2015
In vivo, SAA can displace substantial fraction of the major HDL protein, apoA-I, and thereby influence the structural remodeling and functions of acute-phase HDL in ways that are incompletely understood.
Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study.
Risérus et al., Uppsala, Sweden. In Am J Clin Nutr, 27 Jun 2015
RESULTS: As expected, the control diet increased plasma lipids, whereas the MFGM diet did not [total cholesterol (±SD): +0.30 ± 0.49 compared with -0.04 ± 0.49 mmol/L, respectively (P = 0.024); LDL cholesterol: +0.36 ± 0.50 compared with +0.04 ± 0.36 mmol/L, respectively (P = 0.024); apolipoprotein B:apolipoprotein A-I ratio: +0.03 ± 0.09 compared with -0.05 ± 0.10 mmol/L, respectively (P = 0.007); and non-HDL cholesterol: +0.24 ± 0.49 compared with -0.14 ± 0.51 mmol/L, respectively (P = 0.013)].
Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity.
Cho et al., Kyŏngsan, South Korea. In Mol Cells, 22 Jun 2015
To compare anti-atherogenic properties between apoA-I and apoA-4, we characterized both proteins in lipid-free and lipidbound state.
Zerumbone, A Natural Cyclic Sesquiterpene, Promotes ABCA1-Dependent Cholesterol Efflux from Human THP-1 Macrophages.
Liu et al., Zhengzhou, China. In Pharmacology, 20 Jun 2015
UNASSIGNED: This study was conducted to explore the effect of zerumbone, isolated from Zingiberzerumbet Smith, on apolipoprotein A-I (apoA-I)-mediated cholesterol efflux from THP-1 macrophages.
Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/ LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Wouter Jukema et al., Leiden, Netherlands. In Eur J Pharmacol, 16 Jun 2015
Nonetheless, treatment strategies aimed at improving HDL function and raising apolipoprotein A-I may be worth exploring.
Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo.
Saku et al., Fukuoka, Japan. In Int J Cardiol, 07 Jun 2015
BACKGROUND: We elucidated the effect of newly developed Fukuoka Apolipoprotein A-I Mimetic Peptide (FAMP) on in vivo macrophage reverse cholesterol transport (RCT) and the underlying mechanisms.
Structural stability and functional remodeling of high-density lipoproteins.
Gursky, Boston, United States. In Febs Lett, 05 Apr 2015
A mechanism for the conformational adaptation of the major HDL proteins, apoA-I and apoA-II, to the increasing lipid load is proposed.
ApoA-I mimetics.
Hovingh et al., Amsterdam, Netherlands. In Handb Exp Pharmacol, Dec 2014
ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
HDL in infectious diseases and sepsis.
Norata et al., Cinisello Balsamo, Italy. In Handb Exp Pharmacol, Dec 2014
Pharmacological studies support the benefit of recombinant HDL or apoA-I mimetics during bacterial infection, while apoL-1-nanobody complexes were tested for trypanosome infection.
Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions.
Vuilleumier et al., Genève, Switzerland. In Handb Exp Pharmacol, Dec 2014
The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events.
Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.
Melbye et al., Copenhagen, Denmark. In Jama, 2013
P = 1.9 × 10(-10)), is located 301 bases downstream of the apolipoprotein A-I (APOA1) gene and is correlated (r2 between 0.46 and 0.80) with SNPs previously found to be associated with levels of circulating cholesterol.
Control of angiogenesis by AIBP-mediated cholesterol efflux.
Miller et al., San Diego, United States. In Nature, 2013
To prevent cholesterol overload, ATP-binding cassette (ABC) transporters mediate cholesterol efflux from the cells to apolipoprotein A-I (apoA-I) and the apoA-I-containing high-density lipoprotein (HDL).
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Singh-Jasuja et al., Tübingen, Germany. In Nat Med, 2012
Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival.
Lipid-related markers and cardiovascular disease prediction.
Danesh et al., In Jama, 2012
OBJECTIVE: To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction.
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Rader et al., Philadelphia, United States. In N Engl J Med, 2011
RESULTS: The levels of HDL cholesterol and apolipoprotein A-I were significant determinants of cholesterol efflux capacity but accounted for less than 40% of the observed variation.
Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles.
Sakmar et al., New York City, United States. In J Mol Biol, 2008
The NABB system using engineered zebrafish apo A-I is a native-like membrane mimetic system for G-protein-coupled receptors.
share on facebooktweetadd +1mail to friends